Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | TTR | P02766 | 3/20 | 0.65 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.63 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.63 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.59 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.59 |
| ▸ | APP | P05067 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 2/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8162868 | 0.92 | ALOX5 (0.76) | ALOX5ALDH1A1KDM4ETTRAKR1C3 | |
| SCHEMBL29489692 | 0.92 | ALOX5 (0.76) | ALOX5ALDH1A1KDM4ETTRNFE2L2 | |
| SCHEMBL8162874 | 0.92 | ALOX5 (0.76) | ALOX5ALDH1A1KDM4ETTRAKR1C3 | |
| SCHEMBL8162302 | 0.92 | ALOX5 (0.76) | ALOX5ALDH1A1KDM4EAKR1C3APP | |
| SCHEMBL8162304 | 0.92 | ALOX5 (0.76) | ALOX5ALDH1A1KDM4EAKR1C3APP | |
| SCHEMBL29489695 | 0.92 | ALOX5 (0.83) | ALOX5ALDH1A1KDM4ETTRAKR1C3 | |
| SCHEMBL30219096 | 0.92 | ALOX5 (1.00) | ALOX5ALDH1A1KDM4ETTRNFE2L2 | |
| SCHEMBL9534555 | 0.92 | ALOX5 (0.83) | ALOX5ALDH1A1KDM4ETTRAKR1C3 | |
| SCHEMBL9534542 | 0.92 | ALOX5 (0.83) | ALOX5ALDH1A1KDM4ETTRAKR1C3 | |
| SCHEMBL9533683 | 0.92 | ALOX5 (1.00) | ALOX5ALDH1A1KDM4ETTRNFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107522748-B | Organic electroluminescent material and device | 环球展览公司 | 2024-01-09 | — | — | CN | claimed |
| WO-2025172308-A1 | JOSEPHSON TRAVELLING WAVE PARAMETRIC AMPLIFIER AND METHOD FOR OBTAINING THE SAME | QUANTWARE HOLDING B.V. (NL) | 2025-08-21 | — | — | WO | disclosed |
| US-20240277714-A1 | USE OF SOS1 INHIBITORS WITH RAS INHIBITORS TO TREAT CANCERS | Revolution Medicines, Inc. | 2024-08-22 | — | — | US | disclosed |
| US-20240108630-A1 | METHODS FOR INHIBITING RAS | Revolution Medicines, Inc. | 2024-04-04 | — | — | US | disclosed |
| US-20220235134-A1 | ANTI-B7-H3 ANTIBODIES | SINGLE CELL TECHNOLOGY, INC. (US) | 2022-07-28 | — | — | US | disclosed |
| EP-3976660-A1 | ANTI-B7-H3 ANTIBODIES | Single Cell Technology, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277714-A1 | USE OF SOS1 INHIBITORS WITH RAS INHIBITORS TO TREAT CANCERS | SOS1, HRAS, KRAS | ALOX5 4441/4885ALDH1A1 4139/4885KDM4E 4024/4885 |
| US-20240108630-A1 | METHODS FOR INHIBITING RAS | KRAS, HRAS, NRAS | ALOX5 4608/4885ALDH1A1 4098/4885KDM4E 2735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.